Reportedly, Indonesia will produce drugmaker Merck’s (MRK) vaccines for human papillomavirus (HPV), informed the chief of its state-owned pharmaceutical company Bio Farma in a bid to combat HPV-linked cervical cancer in the country.
Honesti Basyir, chief of Bio Farma, signed a technology transfer deal with Merck & Co, one of the world’s main makers of HPV vaccines, to help produce the Merck shots in the country. The country authorities aim to give the shots to 1.4 million girls next year, adding it aims to produce 2.8 million doses given the two-shot regime recommended to inoculate against HPV-linked cervical cancer.
Merck & Co., Inc. (MRK) is a global healthcare solutions provider that has been working towards bringing forward medicine and vaccines for some of the world’s most challenging diseases for more than a century. They are committed to increasing healthcare access and continue to be at the leading edge of research. Merck has the industry’s largest immuno-oncology clinical research program. To learn more about Merck (MRK) and to track its ongoing progress please visit the Vista Partners Merck Coverage Page.
If you liked this story please consider, visiting the Atossa Therapeutics (ATOS) dedicated page at Vista Partners to learn about the Seattle-based clinical-stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a current focus on breast cancer and lung injury caused by cancer treatments.
